Thirty-six out of sixty-two cases of myelomatosis have been treated with melphalan.
Introduction
Melphalan (phenylalanine mustard) is now generally accepted as a potent drug in the treatment of myelomatosis. Different authors have taken different criteria as indices of successful treatment. Waldenstrom (1964) for instance regards the return of serum protein anomalies to normal as an important criterion; Speed, Galton & Swan (1964) , the overall symptomatic improvement, and the Acute Leukaemia Cooperative Group, an improvement in survival times.
The present report of sixty-two cases with proven myelomatosis (thirty-six of whom were treated with melphalan) aims to outline some particular problems in the management of this disease and to assess the relative survival times of those treated with melphalan against those not so treated.
Several problems emerge in the other surveys of the treatment of this disease. Firstly there is a relatively high mortality in the early months after diagnosis and the start of treatment.
Secondly, there appears to be an improvement in the median survival time of patients treated with melphalan but in the great majority of cases the treated patients will die of the disease or one of its complications. Thirdly, melphalan fails to control the disease in some cases (two cases in this series) and there may be progressive osteoporosis or anaemia indicating drug resistence or marrow failure. Fourthly, the frequent attendance of patients at a hospital for clinical assessment and haematological review presents a strain on the patient and may overtax the resources of some smaller departments.
Material
The series consists of sixty-two cases of proved myelomatosis, the diagnoses being based on finding an excess of typical myeloma cells in the bone marrow, a monoclonal type of increase in serum globulins on electrophoresis and the finding of Bence Jones protein in the urine. All patients had one or more of these significant abnormalities. Radiological evidence of myelomatosis has been present in many patients. The patients surveyed comprise all those seen in this department since 1958, the time at which melphalan became readily available.
Methods
In this analysis patients fall into one of four groups of treatment:
1. Patients receiving no specific anti-tumour treatment Eleven cases in this series were given no specific treatment for myelomatosis because they came under care at a stage when they appeared moribund. In spite of this however two patients in this group continue to survive in good health a number of years after their presentation and they have needed no specific treatment since.
Radiotherapy group
Nine patients come in this group and all presented early in the period under review. Radio- therapy was usually given extensively to the spine or to local areas in which there was pain; radioactive phosphorus has been given intravenously to some patients to produce whole-body irradiation.
Other chemotherapeutic agents
These were given to six patients and the agents used were either urethane, cyclophosphamide or nitrogen mustard.
Patients treated with melphalan
This drug was given to thirty-six patients. In common with many other centres we were uncertain of the optimum dosage regime. Initially we employed an oral dose based on the patient's weight, of 0-075mg/kg day for 10 days. At this time, however, the lag-response of the haemopoietic system and the wide range of individual sensitivity to the drug were not appreciated. Some cases produced profound toxic symptoms whilst others achieved little or no benefit from melphalan given in this dosage.
As has been noted by the Acute Leukaemia Co-operative Group B, we found that the most valuable parameter to use as a guide in the initial dosage was the platelet count, the dose being adjusted to bring the count down to 150,000 cells/mm3. The therapeutic ratio seems to be particularly narrow when the drug is first started, but subsequently melphalan can be given on a more empirical dose/weight programme. The point at which one changes to the latter is based on clinical findings, particularly the patient's subjective improvement; special tests and radiographs will not necessarily reflect this improvement until later in the course of treatment, if at all.
Maintenance therapy using melphalan is based on intermittent courses given at intervals of 12 weeks and lasting 1 week. Seventy milligrams are given orally (as is the initial course) in 1 week for a patient of average build (70 kg), that is 0 15 mg/kg day. Prior to 1963, our maintenance dose was 0 10 mg/kg/day, but since starting the higher dosage, we have been able to achieve a better survival (Fig. 2) 
Mortality in the early months after diagnosis
The somewhat inelastic regime adopted when melphalan was first used led to over-dosage in some patients. This resulted in severe haemorrhagic episodes due to thrombocytopenia in seven patients which were fatal in five. In another seven patients neutropenia was severe enough to contribute to a fatal lung infection. However, since 1963 when the initial treatment was altered these complications have not been seen and there has been a distinct improvement in the percentage of patients surviving the first 6 months of treatment (Fig. 2) 
Discussion
In this series of patients with myelomatosis treatment with melphalan has improved their survival about three-fold over patients not treated or treated by radiotherapy alone. In addition to the improvement in survival we have been impressed by the symptomatic improvement experienced by our patients and which has been observed already in other centres.
Although melphalan should in our opinion be considered the mainstay of therapy for this disease, there are other important modes of treatment which should be available and should be used when there is any indication that the response to melphalan is slow or incomplete. These include radiotherapy, other chemotherapeutic agents such as cyclophosphamide and additional supportive treatment with blood transfusion and androgenic or adrenocortical steroids which may help to combat anaemia and neutropenia.
A comparative study of available chemotherapeutic agents should be interesting in terms of pure survival but we feel it is important not to introduce too rigid a format for the management of individual cases as the addition of more than one form of treatment may be beneficial, particularly if resistance to one or other drug tends to occur. Having achieved a median survival-time of 25 months it should be possible to take treatment a stage further and produce a survival pattern closer to the normal non-malignant survival curve. Treatment in reverse-barrier wards to avert infection and the dialysis of patients showing renal failure together with the use of donor-marrow transfusion may all be methods of treatment worth exploring to enhance the present rates of survival.
Although melphalan is a potent and useful drug it appears to have a rather narrow therapeutic margin of use and without particular care death in the early stages of disease may be partly brought about by this treatment. Other agents such as cyclophosphamide undoubtedly have a safer therapeutic margin. Where dosage control based on frequent blood counts cannot be carried out results as favourable may be expected. After the initial period of close haematological supervision it has only been our practice to review patients at monthly intervals. This has been possible because of the intermittent administration of the drug; other centres which have given continuous chemotherapy have required patients to attend twice a week for blood counts which results in an additional burden on patients and technical staff. Although we would like to increase the interval between hospital attendances if possible, the occurrence of unexpected neutropenia or new symptoms occurring between visits has prevented us extending the monthly intervals of attendance.
